PMV Pharmaceuticals
PMVP
64 hedge funds and large institutions have $52.5M invested in PMV Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 9 closing their positions.
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
43% more capital invested
Capital invested by funds: $36.8M → $52.5M (+$15.7M)
19% more funds holding
Funds holding: 54 → 64 (+10)
4% more ownership
Funds ownership: 66.76% → 70.75% (+4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
28% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$6.62M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$848K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$725K |
| 4 |
Jane Street
New York
|
+$529K |
| 5 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$404K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
-$2.48M |
| 2 |
SCM
Sio Capital Management
New York
|
-$1.52M |
| 3 |
D.E. Shaw & Co
New York
|
-$819K |
| 4 |
O
OrbiMed
New York
|
-$692K |
| 5 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
-$346K |
PMVP Hedge Fund Activity: Q3 2025 in Review
64 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q3 2025, worth a combined $52.5M — up 43% from $36.8M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new PMVP positions and 9 closed out — a net gain of 10 holders — while 13 added to existing stakes and 18 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $6.62M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $2.48M sold.
- 64 institutional investors held PMV Pharmaceuticals (PMVP) as of Q3 2025, up from 54 in Q2 2025.
- Funds reported $52.5M of PMV Pharmaceuticals stock for Q3 2025, up 43% quarter-over-quarter.
- 19 funds opened new PMV Pharmaceuticals positions in Q3 2025 and 9 closed out, a net change of +10 holders.
- The largest PMV Pharmaceuticals buyer in Q3 2025 was Tang Capital Management, an estimated $6.62M added.
- The largest PMV Pharmaceuticals seller in Q3 2025 was Alkeon Capital Management, an estimated $2.48M sold.
Based on aggregated 13F filings for Q3 2025.